知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.02 秒)

    COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES
    2.
    发明申请
    COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES 有权

    公开(公告)号：US20220202967A1

    公开(公告)日：2022-06-30

    申请号：US17606226

    申请日：2020-04-24

    申请人： ACTINIUM PHARMACEUTICALS, INC.

    发明人： Dale Ludwig ,  Eileen Geoghegan

    IPC分类号： A61K51/10 ,  A61P37/06 ,  A61P35/00

    摘要： Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed. The methods generally include administering to the subject an effective amount of a radiolabeled antibody against CD19, CD20, CD33, CD38, CD45RA, CD52, or a combination thereof. The effective amount of the radiolabeled antibody depletes at least 50% of the targeted immune cells, and less than 20% of the subject's stem cells. When used alone, these methods may target lymphomas, leukemias, and myelomas, and/or may additionally allow repopulation of non-autoreactive immune cells in patients with an autoimmune disease. When these methods precede certain cell-based therapies, such as adoptive cell therapy and/or hematopoietic stem cell therapy, the methods are able to enhance the outcome of the cell-based therapies while minimizing adverse effects.

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
    3.
    发明授权
    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic 有权

    公开(公告)号：US11364235B2

    公开(公告)日：2022-06-21

    申请号：US16607168

    申请日：2018-04-26

    申请人： Actinium Pharmaceuticals, Inc.

    发明人： Dragan Cicic

    IPC分类号： A61K31/496 ,  A61P35/02 ,  A61K51/10 ,  C07K16/28

    摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

    METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    4.
    发明申请
    METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES 审中-公开

    公开(公告)号：US20200276339A1

    公开(公告)日：2020-09-03

    申请号：US16766009

    申请日：2018-12-04

    申请人： Actinium Pharmaceuticals, Inc.

    发明人： Mark Berger

    IPC分类号： A61K51/10 ,  A61K31/7076 ,  A61K31/10 ,  A61K31/675 ,  A61K31/198 ,  A61K35/28 ,  A61P35/02

    摘要： Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.

    METHOD FOR THE PURIFICATION OF RADIUM FROM DIFFERENT SOURCES
    6.
    发明申请
    METHOD FOR THE PURIFICATION OF RADIUM FROM DIFFERENT SOURCES 有权
    从不同来源净化辐射的方法

    公开(公告)号：US20120251415A1

    公开(公告)日：2012-10-04

    申请号：US13441803

    申请日：2012-04-06

    申请人： Eva KABAI ,  Josue M. MORENO BERMUDEZ ,  Richard HENKELMANN ,  Andreas Türler

    发明人： Eva KABAI ,  Josue M. MORENO BERMUDEZ ,  Richard HENKELMANN ,  Andreas Türler

    IPC分类号： C01F13/00

    CPC分类号： C22B60/00 ,  C22B3/002 ,  C22B13/04 ,  C22B26/20 ,  G21G1/001 ,  G21G2001/0094 ,  Y02P10/234

    摘要： The invention is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225Ac. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.

    摘要翻译： 本发明涉及一种用于纯化镭（特别是226Ra）的方法，用于使用提取色谱从化学上类似的元素如Ba，Sr和Pb分离用于从可用的放射源制备基本上纯的225Ac产物的目标制备 从所需的Ra; 其中所述提取色谱法具有基于冠醚的萃取剂体系。 本发明涉及一种用于回收226Ra的方法，用于在分离产生的225Ac之后，用加速质子（p，2n）照射的镭源进行225Ac生产的目标制备。 在该方法中，使用上述提取色谱和阳离子交换层析的组合。 得到的226Ra基本上不含由Ag，Al，As，Be，Bi，Ca，Cd，Co，Cr，Cu，Fe，Ga，K，Li，Mg，Mn，Na，Ni，Pb组成的以下化学污染物 ，Sr，V，Zn和Ba。

    Radium target and method for producing it
    7.
    发明申请
    Radium target and method for producing it 有权
    镭目标及其生产方法

    公开(公告)号：US20070153954A1

    公开(公告)日：2007-07-05

    申请号：US11589551

    申请日：2006-10-30

    申请人： Mark Harfensteller ,  Ernst Huenges ,  Michael Schilp ,  Josue Bermudez

    发明人： Mark Harfensteller ,  Ernst Huenges ,  Michael Schilp ,  Josue Bermudez

    IPC分类号： G21G1/10

    CPC分类号： H05H6/00 ,  A61K51/1282 ,  G21G1/10

    摘要： The present invention refers to a method for producing a radium target for the production of radionuclides by means of accelerated protons, whereby at least one radium containing material out of an aqueous-organic solution or suspension of such a material is applied by means of a dispersing device on a surface in such a way that the dispersing device and the surface are moving relatively towards each other and that the solvent is removed substantially spontaneously. Further, the invention refers to a radium target that is created in such a way that it may exhibit an activity of up to 1.5 curie. The radium targets according to the present invention serve for the production of the radionuclide 225Ac, which may be used in nuclear medicine in the treatment of cancer, particularly in form of its daughter nuclide 213Bi.

    摘要翻译： 本发明涉及通过加速质子制造用于生产放射性核素的镭靶的方法，其中通过分散剂施加至少一种含有有机溶液或这种材料的悬浮液的含镭射材料， 装置以使分散装置和表面相对朝向彼此移动并且基本上自发地去除溶剂的方式。 此外，本发明涉及一种镭目标，其以这样一种方式产生，其可以表现出高达1.5居里的活性。 根据本发明的镭靶标用于生产放射性核素225A，其可用于治疗癌症的核医学，特别是其子核素的形式， / SUP> Bi。